One Peak Makes 6x Return on Sale of Leading AI-Driven Legal Operations Platform Brightflag to Wolters Kluwer
29.5.2025 17:49:00 CEST | Business Wire | Press Release
One Peak, a leading specialist growth equity investor, announces that it has entered into a definitive agreement to sell its interest in Shine Analytics Limited (“Brightflag”) to Wolters Kluwer (Euronext: WKL), a global leader in information solutions, software and services for professionals. Brightflag is the leading AI-driven legal operations platform, enabling corporate legal departments globally to drive visibility, automation and cost-control across the legal function.
One Peak made a significant minority investment in Brightflag in December 2020, backing a strong and experienced management team led by Ian Nolan and Alex Kelly, with the goal of building a category-defining leader within the large and rapidly growing enterprise legal management market. One Peak partnered closely with Brightflag to accelerate growth through international expansion and AI-led product innovation, establishing Brightflag as the leading AI-driven legal operations platform globally and growing revenues more than 5x since One Peak’s investment.
Ian Nolan, Co-Founder and CEO of Brightflag, said “We’re incredibly proud of what we have achieved over the past years and One Peak has been instrumental in helping us realize our global ambitions. The One Peak team’s deep knowledge of the legal technology sector and their growth-oriented operational expertise has been invaluable to our success and expansion.”
Alex Kelly, Co-Founder and COO of Brightflag, added “From the early days of our partnership, One Peak distinguished itself as a trusted and passionate supporter of our vision. They’ve stood by us through thick and thin, bringing not only a deep understanding of our business and product but also acting as invaluable sparring partners at every stage. We’re deeply thankful for their belief in Brightflag and the collaborative spirit they brought to our journey.”
Humbert de Liedekerke Beaufort, Co-Founder and Managing Partner of One Peak, added “It has been a true privilege to partner with Ian, Alex, and the entire Brightflag team on their incredible journey. From day one, their vision, drive, and unwavering commitment to transforming legal operations set them apart. We’re proud to have played a part in their growth story and are deeply grateful for the trust, collaboration, and shared ambition that defined our partnership. We wish them continued success in this exciting new chapter.”
The transaction is subject to customary closing conditions and is expected to complete in June 2025. Brightflag and its shareholders were advised by William Blair, Proskauer Rose and Maples.
About One Peak
One Peak is a leading specialist growth equity firm that invests in technology companies in the scale-up phase. One Peak provides growth capital, operating expertise, and access to its extensive network to exceptional entrepreneurs, with a view to help transform innovative and rapidly growing businesses into lasting, category-defining leaders. One Peak’s investments include Akur8, Ardoq, Cymulate, Deepki, Docplanner, Iplicit, Keepit, Lucca, Neo4j, PandaDoc, Spryker, and many others. To learn more, visit www.onepeak.tech.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250529239750/en/
Contacts
For all media inquiries, please contact Olivia Ewin at pr@onepeak.tech.
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press Release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press Release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press Release
Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press Release
ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, frustrated with outdated tools, or looking to connect with peers solving similar problems and putting AI to work. Renowned technology analyst and former Andreessen Horowitz
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom